Mycobacterium chelonei: friend or foe?

McGrath E. E., Qureshi N.

Source: Eur Respir J 2007; 30: 397
Journal Issue: August

Full text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
McGrath E. E., Qureshi N.. Mycobacterium chelonei: friend or foe?. Eur Respir J 2007; 30: 397

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Bacterial colonisation in COPD: friend or foe?
Source: Annual Congress 2010 - PG11 Postgraduate Course: Infection: a player in the natural history of COPD
Year: 2010



Infection: friend or foe to the development of asthma?
Source: Eur Respir J 2001; 18: 744-747
Year: 2001


Pulmonary Mycobacterium abscessus: can we identify the road to improved outcomes?
Source: Eur Respir J, 54 (1) 1901121; 10.1183/13993003.01121-2019
Year: 2019



Mycobacterium tuberculosis, how long did you walk?
Source: Annual Congress 2013 –Tuberculosis: clinical epidemiology and public health
Year: 2013


Human-to-human transmission of Mycobacterium kansasii or victims of a shared source?
Source: Eur Respir J 2014; 44: 1085-1087
Year: 2014


Pulmonary diseases caused by non-tuberculous mycobacteria
Source: Eur Respir Mon 2012; 58: 25-37
Year: 2012


Recurrent laboratory pseudo-outbreaks of Mycobacterium intracellulare
Source: Annual Congress 2008 - Aetiology of respiratory infections: mycobacteria and fungi
Year: 2008

The new “Hesitation Blues”: initiating Mycobacterium avium complex lung disease therapy
Source: Eur Respir J , 49 (3) 1700110; DOI: 10.1183/13993003.00110-2017
Year: 2017


Clinical relevance of Mycobacterium malmoense isolation in the Netherlands
Source: Eur Respir J 2009; 34: 926-931
Year: 2009



Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments
Source: Eur Respir Rev, 31 (163) 210212; 10.1183/16000617.0212-2021
Year: 2022



Fixed-dose combination and therapeutic drug monitoring in tuberculosis: friend or foe?
Source: Eur Respir J 2016; 48: 1230-1233
Year: 2016


Invasive Mycobacterium avium intracellulare infection
Source: Eur Respir J 2006; 28: Suppl. 50, 312s
Year: 2006

Achromobacter xylosoxidans: Friend or foe?
Source: Annual Congress 2011 - Cystic fibrosis: clinical and laboratory studies
Year: 2011

M. tuberculosis W-strain: MDR or no?
Source: Eur Respir J 2003; 22: Suppl. 45, 555s
Year: 2003

No human transmission of Mycobacterium malmoense in a perfect storm setting
Source: Eur Respir J 2012; 40: 1576-1578
Year: 2012


Untreatable tuberculosis: is surgery the answer?
Source: Eur Respir J 2015; 45: 577-582
Year: 2015


Mycobacterium xenopi pulmonary disease in Croatia
Source: International Congress 2017 – Microbiology and laboratory techniques to monitor NTM infections
Year: 2017